Combined blockade of the IL-13 and IL-33 pathways leads to a greater inhibition of type 2 inflammation over inhibition of either pathway alone

J Allergy Clin Immunol. 2017 Feb;139(2):705-708.e6. doi: 10.1016/j.jaci.2016.08.026. Epub 2016 Sep 30.

Authors

Affiliations

¹ Department of Immunology Discovery, Genentech, South San Francisco, Calif.
² Department of Translational Immunology, Genentech, South San Francisco, Calif.
³ Department of Pathology, Genentech, South San Francisco, Calif.
⁴ Department of Immunology Discovery, Genentech, South San Francisco, Calif. Electronic address: rajitap@gene.com.

PMID: 27697499
DOI: 10.1016/j.jaci.2016.08.026

No abstract available

Publication types

Letter

MeSH terms

Animals
Antibodies, Blocking / immunology
Antibodies, Blocking / pharmacology*
Asthma / genetics
Asthma / immunology*
Asthma / pathology
Disease Models, Animal
Inflammation / drug therapy
Inflammation / genetics
Inflammation / immunology
Inflammation / pathology
Interleukin-13 / antagonists & inhibitors*
Interleukin-13 / genetics
Interleukin-13 / immunology
Interleukin-33 / antagonists & inhibitors*
Interleukin-33 / genetics
Interleukin-33 / immunology
Mice
Mice, Knockout
Nippostrongylus / immunology*
Signal Transduction / drug effects*
Strongylida Infections / drug therapy
Strongylida Infections / genetics
Strongylida Infections / immunology*
Strongylida Infections / pathology

Substances

Antibodies, Blocking
Il33 protein, mouse
Interleukin-13
Interleukin-33